{"id":15812,"date":"2023-07-27T23:19:00","date_gmt":"2023-07-27T15:19:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15812"},"modified":"2024-11-29T23:21:35","modified_gmt":"2024-11-29T15:21:35","slug":"gsk-reports-4-yoy-sales-growth-in-q2-2023-upgrades-full-year-guidance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15812","title":{"rendered":"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance"},"content":{"rendered":"\n

UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK<\/a>) has released its financial report for the second quarter of 2023, demonstrating a robust performance with sales revenues increasing by 4% year-on-year (YOY) in constant currency terms to GBP 7.178 billion (USD 9.3 billion). Excluding COVID-19-related sales, the growth was even more pronounced at 11% YOY.<\/p>\n\n\n\n

CEO Emma Walmsley’s Comments and Guidance Upgrade<\/strong>
CEO Emma Walmsley highlighted that the results reflect the company’s ongoing return to strength and justified an upgrade to the annual guidance for full-year performance. Sales turnover for 2023 is now expected to reach 8%-10%, an increase from the previous projection of 6%-8%.<\/p>\n\n\n\n

Vaccines Unit Outperforms with 18% Growth<\/strong>
The Vaccines unit was a standout performer with growth at 18%, with the shingles vaccine Shingrix enjoying a 20% YOY sales expansion during the quarter. Specialty Medicines sales were down -7%, but excluding COVID, they showed a significant increase of 12%, with HIV sales up 12%. General Medicines sales were up 8%, with the asthma drug Trelegy (fluticasone, umeclidinium, and vilanterol) experiencing a substantial 30% YOY growth.<\/p>\n\n\n\n

Pipeline Catalysts and Market Approvals<\/strong>
GSK boasts a notably strong pipeline with several H2\u201923 pipeline catalysts. The triple-action targeted therapy momelotinib, which targets the JAK1 and 2 pathways as well as activin A receptor, type I (ACVR1), is set for a first market approval for the treatment of myelofibrosis. The programmed death-1 (PD-1) inhibitor Jemperli (dostarlimab) already has clearance for three indications in the US market, and GSK expects to add approval for the drug as a first-line treatment for mismatch repair-deficient (MMRd) endometrial cancer.<\/p>\n\n\n\n

In China, the National Medical Products Administration (NMPA) approved HIV therapy Vocabria (cabotegravir) earlier this month. GSK also anticipates an NMPA decision on IL-5 antibody Nucala (mepolizumab) for an additional indication of chronic rhinosinusitis with nasal polyps (CRSwNP), which would significantly expand the drug’s market compared to its first China indication for the rare disease eosinophilic granulomatosis with polyangiitis (EGPA), awarded in June 2022.<\/p>\n\n\n\n

Decision to Cease Development of Jesduvroq in Europe<\/strong>
GSK has decided to cease development in Europe for its preferred hypoxia-inducible factor\u2013prolyl hydroxylase inhibitor (HIF-PHI) Jesdruvroq (daprodustat), despite recently receiving a positive Committee for Medicinal Products for Human Use (CHMP) opinion for anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The decision was based on a significant reduction in the size of the opportunity and the exclusion of the nondialysis population, as well as the availability of other medicines for patients living with CKD-related anemia. Jesduvroq is already approved in the US for CKD dialysis patients, and development in that market remains unaffected.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,278,184,914],"class_list":["post-15812","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"\nGSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the second quarter of 2023, demonstrating a robust performance with sales revenues increasing by 4% year-on-year (YOY) in constant currency terms to GBP 7.178 billion (USD 9.3 billion). Excluding COVID-19-related sales, the growth was even more pronounced at 11% YOY.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15812\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15812\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-27T15:19:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T15:21:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15812#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15812\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance\",\"datePublished\":\"2023-07-27T15:19:00+00:00\",\"dateModified\":\"2024-11-29T15:21:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15812\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15812#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15812\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15812\",\"name\":\"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-27T15:19:00+00:00\",\"dateModified\":\"2024-11-29T15:21:35+00:00\",\"description\":\"UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the second quarter of 2023, demonstrating a robust performance with sales revenues increasing by 4% year-on-year (YOY) in constant currency terms to GBP 7.178 billion (USD 9.3 billion). Excluding COVID-19-related sales, the growth was even more pronounced at 11% YOY.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15812#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15812\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15812#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance - Insight, China's Pharmaceutical Industry","description":"UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the second quarter of 2023, demonstrating a robust performance with sales revenues increasing by 4% year-on-year (YOY) in constant currency terms to GBP 7.178 billion (USD 9.3 billion). Excluding COVID-19-related sales, the growth was even more pronounced at 11% YOY.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15812","og_locale":"en_US","og_type":"article","og_title":"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15812","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-27T15:19:00+00:00","article_modified_time":"2024-11-29T15:21:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15812#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15812"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance","datePublished":"2023-07-27T15:19:00+00:00","dateModified":"2024-11-29T15:21:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15812"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15812#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15812","url":"https:\/\/flcube.com\/?p=15812","name":"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-27T15:19:00+00:00","dateModified":"2024-11-29T15:21:35+00:00","description":"UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the second quarter of 2023, demonstrating a robust performance with sales revenues increasing by 4% year-on-year (YOY) in constant currency terms to GBP 7.178 billion (USD 9.3 billion). Excluding COVID-19-related sales, the growth was even more pronounced at 11% YOY.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15812#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15812"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15812#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15812"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15812\/revisions"}],"predecessor-version":[{"id":15813,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15812\/revisions\/15813"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}